March 16, 2018
TapImmune released some interesting results this week from a Phase I trial conducted at the Mayo Clinic that will add some spice to that discussion.
March 15, 2018
TPIV200 vaccine candidate showed 90% of patients developed robust and durable antigen-specific immune responses against FRa.
February 19, 2018
TapImmune, an immuno-oncology company in Florida is currently clinically testing a vaccine specifically for triple-negative breast and ovarian cancer.
February 13, 2018
A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer (TNBC).
January 30, 2018
Precision Vaccination highlighted our cancer vaccine, TPIV200 for treating triple-negative breast cancer.
January 27, 2018
Peter Hoang, President and CEO of TapImmune, is enthusiastic about a cancer vaccine under development by TapImmune that could help prevent recurrence of such cancers in women.
January 23, 2018
With new innovations and breakthroughs in the field of immunotherapy TapImmune CEO & President, Peter Hoang has been amazed by the change of pace within the field.
December 27, 2017
TPIV 200 is a vaccine that the immuno-oncology company TapImmune is developing as a treatment for platinum-chemotherapy resistant ovarian cancer or triple-negative breast cancer.
December 6, 2017
TapImmune’s lead candidate, TPIV200, a multiple-epitope anti-folate receptor alpha (FRα) immunotherapy, with an FDA orphan drug designation, has paired up with AstraZeneca’s checkpoint inhibitor Imfinzi in platinum-resistant ovarian cancer patients.
December 1, 2017
Tapimmune Inc. President & CEO, Peter Hoang, participates in an interview with The Wall Street Analyzer. Take a listen.